Sponsor study identifier
observational
240
1 country
1
Study Start
September 29, 2020
Actual (reported)Primary Completion
April 16, 2021
Actual (reported)Study Completion
June 24, 2021
Actual (reported)The purpose of this retrospective observational study is to evaluate the performance of the Shared Decision Making Process scale in a sample of patients who have received a decision aid about the decision to screen or not screen for breast cancer, colon cancer, prostate cancer, or lung cancer.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
June 24, 2021
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
September 29, 2020
Actual (reported)September 29, 2020
Actual (reported)October 23, 2020
Actual (reported)April 16, 2021
Actual (reported)June 24, 2021
Actual (reported)March 30, 2023
Actual (reported)Shared Decision Making Process Measure
The Shared Decision Making Process is a short patient-reported survey that measures the amount of shared decision making that occurs in an interaction. Scores range from 0-4 where higher values indicate a better shared decision making process outcome.
Baseline survey
The 9-item Shared Decision Making Questionnaire
Baseline survey
Decisional Conflict Tool (SURE)
Baseline survey
Women between the ages of 35-55 when they received a decision aid for breast cancer screening with no prior diagnosis of breast cancer. These people will see items only pertaining to breast cancer screening.
Men and women between the ages of 45-75 when they received a decision aid for colon cancer screening with no prior diagnosis of colon cancer. These people will see items only pertaining to colon cancer screening.
Men between the ages of 45-74 when they received a decision aid for prostate cancer screening with no prior diagnosis of prostate cancer. These people will see items only pertaining to prostate cancer screening.
Healthwise patient decision aids for breast, prostate, colon and lung cancer screening provide information on the pros and cons of cancer screening and guidance in process of selecting a choice.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Adults who received a cancer screening decision aid in the last 2 years while receiving care at 4 hospitals within a major healthcare network.
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
Karen R Sepucha, PhD
Massachusetts General Hospital
240 participants (actual enrollment reported by the registry).
First Submitted
September 29, 2020
First Posted
October 23, 2020
Study Start
September 29, 2020
Actual (reported)Single-Item Measure of Decision Regret
Baseline survey
Treatment Choice
Baseline survey
Adapted Controlled Preference Scale
Baseline survey
Contact the study team to confirm eligibility.
Primary Completion
April 16, 2021
Actual (reported)Study Completion
June 24, 2021
Actual (reported)Last Updated
March 30, 2023
Results First Posted
March 30, 2023
Record last verified: 2022-06
The study team will create a complete, cleaned, de-identified copy of the final data set for each cancer screening topic.
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: